WO2004017996A1 - 関節軟骨細胞外マトリクス分解阻害剤 - Google Patents
関節軟骨細胞外マトリクス分解阻害剤 Download PDFInfo
- Publication number
- WO2004017996A1 WO2004017996A1 PCT/JP2003/010460 JP0310460W WO2004017996A1 WO 2004017996 A1 WO2004017996 A1 WO 2004017996A1 JP 0310460 W JP0310460 W JP 0310460W WO 2004017996 A1 WO2004017996 A1 WO 2004017996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- extracellular matrix
- agent
- articular cartilage
- degradation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an articular cartilage extracellular matrix degradation inhibitor useful as a therapeutic agent for joint diseases such as osteoarthritis, rheumatoid arthritis, and osteoarthritis.
- DNA in the cell nucleus forms a nucleosome-based chromatin structure.
- the nucleosome is a structure in which core histones (octamers consisting of two molecules each of histones H2A, H2B, H3, and H4) and DNA are wrapped around, and the positively charged lysine residue at the histone N-terminal is Nucleosome exists in a highly folded state by forming a charge stable state with negatively charged DNA (Wolffe, AR et al Cell 84, 817-819, 1996 ). In order for the transcription reaction of a gene to occur in the nucleus, it is necessary to unravel its structure so that various transcription factors can contact DNA.
- Histones in gene regions where transcription is suppressed have a low degree of acetylation, and histones in gene regions where transcription is actively occurring are strongly acetylated.
- Histones in gene regions where transcription is suppressed have a low degree of acetylation, and histones in gene regions where transcription is actively occurring are strongly acetylated.
- Has previously known Hebbes, TR et al EMBO J. 7, 1395-1402, 1988; Grunstein, M. et al Nature 389, 349-352, 1997.
- the histone lysine residue in the nucleosome is acetylated, its positive charge is neutralized, and the nucleosome structure relaxes, allowing various transcription factors to contact DNA and facilitate transcription.
- HAT histone deacetylase
- HDAC histone deacetylase
- butyric acid which has various actions such as cell cycle arrest, normalization of transformed cell morphology, and induction of differentiation, has been known to accumulate highly acetylated histones in cells and inhibit HDAC.
- TSA microbial metabolite Trichostatin A
- TSA is a potent HDAC inhibitor
- HDAC inhibitors are also being studied. Trapoxin, a microbial metabolite, was known to inhibit cell growth and normalize the morphology of v-sis transformed cells.
- CHAP cyclic hydroxamic acid-containing peptide
- Valproic acid Gott Anlagen, M. EMBO J. 20, 6969-78, 2001
- NVP-LAQ824 Perez, LB et al Proc. Am.Assoc. It has been reported that compounds such as Cancer Res. Abst # 3671, 2002, WO02 / 22577) and Apicidin (Cancer Res. 60, 6068-6074, 2000) have HDAC inhibitory activity.
- a compound in which R is an isopropyl group in Formula (II) is Compound A, a compound in which sec-butyl is R in Formula B, a compound B in which R is an isobutyl group, and a compound C in which R is an isobutyl group in Formula (II).
- the depsipeptide compound represented by (Ila) is abbreviated to reduced compounds A to C, respectively.
- R means an isopropyl group, a sec-butyl group or an isobutyl group.
- HDAC inhibitors are expected to be effective as antitumor agents because they exhibit cell cycle arrest, normalization of transformed cell morphology, differentiation induction, apoptosis induction, and angiogenesis inhibitory action (Non-patent Document 1). And 2).
- treatment and improvement of cell proliferative diseases such as infectious diseases, autoimmune diseases and skin diseases (see Non-patent Document 3), and prevention and treatment of progressive neurodegenerative diseases such as Huntington's disease (See Non-Patent Document 4)
- various applications have been attempted, such as efficient vector transfer in gene therapy (see Non-Patent Document 5), and enhancement of transgene expression (see Non-Patent Document 6).
- Patent Document 1 The patent specification of the FK228 reduced form (Patent Document 1) states that the FK228 reduced form is useful for diseases caused by abnormal gene expression due to its HDAC inhibitory activity. Although rheumatoid arthritis and osteoarthritis are mentioned, there is no specific effect described, nor is there any evidence of a therapeutic effect.
- International Publication WO02 / 055017 pamphlet shows the effect of an HDAC inhibitor on the normal expression of abnormal immune-related genes in T cells collected from patients with systemic lupus erythematosus. Based on this, it is described that it can be used to treat autoimmune diseases including rheumatoid arthritis. However, there is no disclosure of a specific effect on rheumatoid arthritis, and there is no description suggesting that an HDAC inhibitor inhibits degradation and degeneration of extracellular matrix components of articular cartilage.
- Joint diseases such as osteoarthritis, rheumatoid arthritis (RA), and osteoarthritis (OA) mainly involve damage and degeneration of articular cartilage.
- OA is the disease with the largest number of patients, but with current treatment methods, the analgesic and anti-inflammatory drug ⁇ hyaluronan is used as a symptomatic treatment to reduce the pain associated with cartilage degeneration and subchondral bone destruction. It is used only for clinical purposes, and it cannot be said that it has achieved a sufficient therapeutic effect.
- Joint diseases are caused by various causes, such as cartilage surface cracks due to trauma, abnormal autoimmunity, and abnormalities of matrix metallo-orbase, and in the early stage, degradation and degeneration of extracellular matrix in articular cartilage It is commonly observed (see Non-Patent Documents 7 and 8).
- the extracellular matrix is mainly composed of type II collagen and aggrecan, a cartilage-specific proteodalican, and both disruptions cause destruction of the extracellular matrix, leading to destruction of cartilage tissue.
- Non-Patent Documents 79 and 10 described above.
- No therapeutic agent for joint diseases that controls the degradation and degeneration of the extracellular matrix of articular cartilage has been put on the market (see Non-Patent Documents 11 and 12).
- Non-Patent Document 1 Marks, P.A. et al., "Joumal of the National Cancer Institute 2000, Vol. 92, p. 1210-1216
- Non-Patent Document 2 im M.S. et al., "Nature Medicine J 2001, Vol. 7, p. 437-443
- Non-Patent Document 4 Steffan, J.S. et al., ⁇ NatureJ 2001, Vol. 413, p.739-743
- Non-Patent Document 5 Dion, L.D., et al., "Virology”, 1997, Vol.231, ⁇ 201-209
- Non-Patent Document 7 Ishiguro, N, “Separate Volumes, History of Medicine (Extracellular Matrix)”, Medical and Dental Medicine Publishing Co., Ltd., February 25, 1997, p.81-85
- Non-Patent Document 8 Ozaki, S, et al., "Bone to Know: New Medical Treatment for Joint Diseases", Shinko Trading
- Non-Patent Document 9 Lohmander LS. Et al., "Aithritis and Rhettismj 1993, Vol. 36, No. 9, ⁇ ⁇ 1214-22
- Non-Patent Document 10 Ma ait AM. Et al., “Journal of Biological Chemistry 2002, Vol. 277, No. 25, p. 22201-8
- Non-Patent Document 11 Close DR et al., Annals of the Rheumatic Diseases], 2001, Vol. 60, No. 3, p.62-67
- Non-Patent Document 1 2 Arner, EG et al., "Current Opinion in Pharmacology J, 2002, Volume 2, p.322-329
- Patent Document 1 International Publication WO02 / 06307 Breadlet
- Patent Document 2 International Publication WO02 / 055017 Pamphlet Disclosure of the Invention
- the present inventors have conducted intensive studies on the effects of HDAC inhibitory compounds, and found that all HDAC inhibitory compounds having completely different structures have a good effect of inhibiting articular cartilage extracellular matrix degradation.
- the present invention has been completed.
- the present invention relates to an articular cartilage extracellular matrix degradation inhibitor comprising an HDAC inhibitory compound as an active ingredient.
- the present invention relates to a prophylactic or therapeutic agent for osteoarthritis, rheumatoid arthritis, osteoarthritis, etc., which is involved in the degradation and degeneration of articular cartilage extracellular matrix.
- the present invention also relates to an agent for preventing or treating extracellular matrix degradation of articular cartilage in osteoarthritis, rheumatoid arthritis, osteoarthritis and the like, which comprises an HDAC inhibitory compound as an active ingredient.
- the present invention also relates to the use of an HDAC-inhibiting compound for the manufacture of a medicament for inhibiting articular cartilage extracellular matrix degradation.
- the present invention relates to a method for preventing and treating a disease caused by degradation of articular cartilage extracellular matrix, which method comprises administering to a patient a therapeutically effective amount of an HDAC inhibitory compound.
- the present invention has the potential that an HDAC inhibitory compound involved in transcriptional regulation may unexpectedly suppress the degradation and degeneration of extracellular matrix, which is a major lesion of osteoarthritis, and play a central role in the treatment of osteoarthritis. It is a discovery and a truly revolutionary invention.
- the HDAC inhibitory compound used in the medicament of the present invention is a compound that inhibits HDAC and a salt thereof, and specifically, a known HDAC inhibitory compound, FK228 and its reduction , Depsipeptide compounds (compounds A, B and C) and their reduced forms, MS-27-275, Trichos.tatin A, NVP-LAQ824, SAHA, Apicidin, butyric acid and its derivatives (Phenylbutyrate, Pivaloyloxvmetyl butyrate, Valproic acid Etc.), CI-994, Depudecin, Trapoxin and CHAP.
- HDAC inhibitory compounds are commercially available or can be obtained using methods known in the literature.
- FK228 and its reduced form debutpeptide compounds (compounds A, B and C) and their reduced forms, MS-27-275, Trichostatin A, NVP-LAQ824, SAHA, Apicidin, Phenylbuty rate and Valproic acid
- FK228 and its reduced form depsipeptide compounds (compounds ⁇ , ⁇ and C) and their reduced forms, MS-27-275, Trichostatin A, NVP-LAQ824, SAHA and Apicidin .
- Derivatives of these compounds having the same action are also suitable as the HDAC inhibitor of the present invention.
- the HDAC inhibitory activity can be easily measured according to a known general method, for example, the method described in Yoshida, M. et al J. Biol. Chem. 265, 17174-17179, 1990. Specifically, for the prepared literature SL mounting method [3 H] ⁇ cetyl histones and using histone de Asechiru enzyme fraction, a test compound containing [3 H] ⁇ cetyl histones and DTT reaction The mixture was added to the solution, pre-incubated at room temperature for 1 hour, mixed with the histone deacetylase fraction, reacted at room temperature for 2 hours, added with 1M hydrochloric acid and ethyl acetate, and then separated by centrifugation. The measurement can be performed by measuring the radioactivity in the layer with a liquid scintillation counter.
- HDAC inhibitory activity of a representative HDAC inhibitory compound is shown together with the cited reference.
- Compound A shows the results measured by the above method.
- Butyrates butyric acid, Phenylbutyrate, etc.
- raM order Namate. Rev. Drug Discov. 2002 1, 287-299, 2002
- Tric ostatin A 2.1 nM (IC 50 value; Exp. Cell Res. 241, 126-133, 1998)
- NVP-LAQ824 0.03 JLM. (IC 5 value; Blood First Edition Paper, prepublished online June 19, 2003)
- Another preferred HDAC inhibitory compound of the present invention is a compound having an HDAC inhibitory activity (IC 5 o value) of 100 or less, more preferably 10 M or less, and still more preferably 1 / M or less, as measured by the method of Yoshida et al. is there.
- compositions containing one or more HDAC-inhibiting compounds as active ingredients can be converted into tablets, powders, and fine granules using commonly used pharmaceutical carriers, excipients, and other additives. , Granules, capsules, pills, solutions, injections, suppositories, ointments, patches, etc., and are administered orally or parenterally.
- the clinical dose of the HDAC inhibitor compound to humans can be appropriately set depending on the type of the HDAC inhibitor compound.
- about 0.001 to 500 mg, preferably 0.01 to 300 mg per day is appropriate, and it is administered once or in 2 to 4 times.
- intraarticularly, intramuscularly, subcutaneously or intravenously about 0.0001 to 100 mg, preferably 0.001 to 10 mg per administration is appropriate.
- the administration frequency and dosage are appropriately determined in consideration of the symptoms, age, sex, etc., depending on the individual case.
- the one or more active compounds comprise at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polybutylpyrrolidone. , Aluminum metasilicate It is mixed with magnesium phosphate.
- the composition may contain, in a conventional manner, additives other than inert diluents, for example, lubricating agents such as magnesium stearate, disintegrating agents such as calcium cellulose glycolate, and stabilizers and solubilizing agents. May be contained. If necessary, tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate or a film of a gastric or enteric compound.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and commonly used inert diluents such as purified Contains water and ethyl alcohol.
- This composition may contain, in addition to the inert diluent, auxiliary agents such as a solubilizing agent, a wetting agent, and a suspending agent, a sweetening agent, a flavoring agent, a flavoring agent, and a preservative.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Diluents for aqueous solutions and suspensions include, for example, distilled water for injections and saline.
- examples of diluents for water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethyl alcohol, and polysorbate 80 (trade name).
- Such compositions may further comprise additives such as tonicity agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers (eg, lactose), solubilizing agents.
- solubilization treatment known methods applicable to pharmaceutical preparations, for example, a method of adding a surfactant, and formation of a solid dispersion of a drug and a solubilizer, for example, a polymer (a water-soluble polymer or an enteric polymer) Method.
- Example 1 (1) Proteodalican (PG) destruction inhibitory activity in primary cultured heron cartilage cells (retinoic acid stimulation)
- Egret Japanese white species, female, 1.0-: 1.5 kg was killed under over anesthesia, the knee joint was excised, and the cartilage layer on the joint surface was peeled off with a scalpel and shredded.
- trypsin-EDTA trypsin-EDTA
- the cells were seeded on a 96-well plate (manufactured by Asahi Techno Glass Co.) coated with type I collagen at 200 ⁇ / well. Three days later, the medium was replaced with 200/1 DMEM / 10% FBS medium containing 50 / g ml ascorbic acid (hereinafter referred to as ascorbic acid medium), and the culture was further repeated twice for two days. Thereafter, ⁇ Sa formic knee articular cartilage primary culture cells at a final concentration of 10 H Ci / ml of Na 2 35 S0 4 containing Asukorupin acid medium 200
- the cells were washed three times with 2001 ascorbic acid medium and cultured for 1 day in 20011 ascorbic acid medium.
- the cells were stimulated with a 1 M final concentration of all-trans retinoic acid (manufactured by Sigma), and 48 hours later, the culture supernatant was collected in 20 I portions, and the radioactivity was measured using TopCount (Packard's restriction).
- the test compound was added at the same time as the start of stimulation, and its PG degradation inhibitory activity was calculated as a percentage with the retinoic acid-free group being 100 % and the retinoic acid-added group being 0%.
- Example 2 PG destruction inhibitory activity in primary culture cells of egret cartilage (IL-1 stimulation)
- Example 2 In the same manner as in Example 1, primary cultured egret cartilage cells were prepared. Stimulate with human IL-li3 (R & D System) at a final concentration of lOng / ml, collect the culture supernatant 20 hours after 48 hours, and measure the radioactivity using Topcount (Packard) did. The test compound was added at the same time as the start of stimulation, and the PG degradation inhibitory activity was calculated as a percentage with the IL-1 non-addition group being 100% and the IL-1 addition group being 0%.
- human IL-li3 R & D System
- Topcount Topcount
- test methods of Examples 1 and 2 described above have been widely used as a simple evaluation method for evaluating the effect of a test compound on articular cartilage, particularly the effect on degradation and degeneration of extracellular matrix, and have been widely used for screening of therapeutic agents for joint diseases. This is the method used (Spirito S. et al, Agents Actions; 39, C160-2, 1993).
- a matrix meta-oral protease inhibitor that has the effect of inhibiting PG degradation by retinoic acid or IL-1 in vitro (Lawrence J. et al, Arch Biochem Biophys. 344 (2), 404-12, 1997) has been confirmed to suppress the degradation and degeneration of extracellular matrix well in osteoarthritis model mice (Aim Rheum Dis.
- the HDAC inhibitory compound which is an active ingredient of the present invention, which has been confirmed to have excellent effects in this evaluation system, is useful as a drug for suppressing the degradation and degeneration of the extracellular matrix of articular cartilage.
- the HDAC-inhibiting compound which is an active ingredient of the present invention, is suitable for articular chondrocyte cells with respect to both IL-1 and retinoic acid, which are typical stimulators that cause the degradation and degeneration of the cartilage extracellular matrix. It has the action of inhibiting the degradation and denaturation of the extracellular matrix, and is useful as a drug that inhibits the degradation and denaturation of the extracellular matrix of chondrocytes regardless of the type of stimulant.
- the HDAC inhibitory compound which is an active ingredient of the medicament of the present invention, favorably inhibits the degradation of the extracellular matrix of articular cartilage. Degradation of bone extracellular matrix. Useful as a preventive or therapeutic agent for osteoarthritis, rheumatoid arthritis, osteoarthritis, etc. involving degeneration.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03792716A EP1547617B1 (en) | 2002-08-20 | 2003-08-19 | Arthrodial cartilage extracellular matrix degradation inhibitor |
CA002495354A CA2495354A1 (en) | 2002-08-20 | 2003-08-19 | An agent for inhibiting articular cartilage extracellular matrix degradation |
AU2003254951A AU2003254951A1 (en) | 2002-08-20 | 2003-08-19 | Arthrodial cartilage extracellular matrix degradation inhibitor |
US10/525,015 US20050272647A1 (en) | 2002-08-20 | 2003-08-19 | Arthrodial cartilage extracellular matrix degradation inhibitor |
DE60332367T DE60332367D1 (de) | 2002-08-20 | 2003-08-19 | Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel |
JP2004530568A JP4804004B2 (ja) | 2002-08-20 | 2003-08-19 | 関節軟骨細胞外マトリクス分解阻害剤 |
AT03792716T ATE465757T1 (de) | 2002-08-20 | 2003-08-19 | Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-239203 | 2002-08-20 | ||
JP2002239203 | 2002-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004017996A1 true WO2004017996A1 (ja) | 2004-03-04 |
Family
ID=31943856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010460 WO2004017996A1 (ja) | 2002-08-20 | 2003-08-19 | 関節軟骨細胞外マトリクス分解阻害剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050272647A1 (ja) |
EP (1) | EP1547617B1 (ja) |
JP (2) | JP4804004B2 (ja) |
AT (1) | ATE465757T1 (ja) |
AU (1) | AU2003254951A1 (ja) |
CA (1) | CA2495354A1 (ja) |
DE (1) | DE60332367D1 (ja) |
ES (1) | ES2342378T3 (ja) |
WO (1) | WO2004017996A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000282A3 (en) * | 2003-06-25 | 2005-04-28 | G2M Cancer Drugs Ag | Inhibitors of histone deacetylases for the suppression therapy of diseases |
EP1719508A1 (en) * | 2005-05-06 | 2006-11-08 | Yih-Lin Chung | Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction |
KR100844061B1 (ko) * | 2005-02-05 | 2008-07-04 | 재단법인서울대학교산학협력재단 | 히스톤 탈아세틸라제에 대한 저해제 및 이를 이용한 골다공증의 치료 방법 |
WO2010013498A1 (ja) | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | 変形性関節症治療剤又は予防剤 |
JP2010510302A (ja) * | 2006-11-23 | 2010-04-02 | ユニバーシティ、オブ、サウサンプトン | デプシペプチドおよびその治療的使用 |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2011093081A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療剤を含有する注射剤 |
WO2011093083A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
WO2011093082A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療剤または予防剤を製造するための使用 |
JP2011529023A (ja) * | 2008-05-22 | 2011-12-01 | カルス セラピューティクス リミテッド | デプシペプチドおよびその治療的使用 |
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2417682A (en) * | 2004-08-18 | 2006-03-08 | Univ East Anglia | Histone deacetylse inhibitor for treating connective tissue disorders |
EP1965824A4 (en) * | 2005-11-18 | 2011-10-19 | Gloucester Pharmaceuticals Inc | METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228 |
WO2007114697A1 (en) * | 2006-03-31 | 2007-10-11 | Erasmus University Medical Center Rotterdam | Novel composition for tumor growth control |
AU2007323215B2 (en) * | 2006-11-22 | 2012-07-19 | Karus Therapeutics Limited | Depsipeptides and their therapeutic use |
CN101687010A (zh) * | 2006-12-29 | 2010-03-31 | 格洛斯特制药公司 | 制备Romidepsin |
GB0715750D0 (en) * | 2007-08-13 | 2007-09-19 | Karus Therapeutics Ltd | Chemical compounds |
EP2293845A1 (en) * | 2008-05-22 | 2011-03-16 | Karus Therapeutics Limited | Depsipeptides and their therapeutic use |
JP6102993B2 (ja) * | 2015-07-14 | 2017-03-29 | 株式会社大林組 | セメント組成物 |
US20180353447A1 (en) * | 2015-11-27 | 2018-12-13 | Birrbeheer B.V. | Butyrate salts for use in inflammatory diseases |
JP6858838B2 (ja) * | 2016-03-23 | 2021-04-14 | チュー,ショーン | 差動操舵式および前輪操舵式車両のための回生差動装置 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013289A1 (en) * | 1993-11-10 | 1995-05-18 | Chiroscience Limited | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases |
JP2001348340A (ja) * | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
JP2001354694A (ja) * | 2000-06-13 | 2001-12-25 | Yamanouchi Pharmaceut Co Ltd | ジチオール誘導体 |
WO2002006307A1 (fr) * | 2000-07-17 | 2002-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Fk228 reduit et son utilisation |
WO2002022577A2 (en) * | 2000-09-01 | 2002-03-21 | Novartis Ag | Hydroxamate derivatives useful as deacetylase inhibitors |
WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0827742A1 (en) * | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
ATE470447T1 (de) * | 1999-12-08 | 2010-06-15 | Cyclacel Pharmaceuticals Inc | Depsipetid und kongenere davon für den einsatz als immunsuppressiva zur vorbeugung und behandlung von abstossreaktionen infolge einer transplantation und zur induktion des apoptosis in aktivierten cd4 oder cd8 t-zellen |
US6522065B1 (en) * | 2000-03-27 | 2003-02-18 | General Electric Company | Single phosphor for creating white light with high luminosity and high CRI in a UV led device |
WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
DE60113645T2 (de) * | 2001-04-10 | 2006-07-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten |
US7199227B2 (en) * | 2001-06-14 | 2007-04-03 | Bristol-Myers Squibb Company | Polynucleotides encoding human histone deacetylase HDAC9c |
PL212089B1 (pl) * | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja |
TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
-
2003
- 2003-08-19 DE DE60332367T patent/DE60332367D1/de not_active Expired - Lifetime
- 2003-08-19 WO PCT/JP2003/010460 patent/WO2004017996A1/ja active Application Filing
- 2003-08-19 US US10/525,015 patent/US20050272647A1/en not_active Abandoned
- 2003-08-19 AU AU2003254951A patent/AU2003254951A1/en not_active Abandoned
- 2003-08-19 AT AT03792716T patent/ATE465757T1/de not_active IP Right Cessation
- 2003-08-19 JP JP2004530568A patent/JP4804004B2/ja not_active Expired - Fee Related
- 2003-08-19 CA CA002495354A patent/CA2495354A1/en not_active Abandoned
- 2003-08-19 EP EP03792716A patent/EP1547617B1/en not_active Expired - Lifetime
- 2003-08-19 ES ES03792716T patent/ES2342378T3/es not_active Expired - Lifetime
-
2008
- 2008-12-26 JP JP2008331707A patent/JP2009137979A/ja not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013289A1 (en) * | 1993-11-10 | 1995-05-18 | Chiroscience Limited | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases |
JP2001348340A (ja) * | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
JP2001354694A (ja) * | 2000-06-13 | 2001-12-25 | Yamanouchi Pharmaceut Co Ltd | ジチオール誘導体 |
WO2002006307A1 (fr) * | 2000-07-17 | 2002-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Fk228 reduit et son utilisation |
WO2002022577A2 (en) * | 2000-09-01 | 2002-03-21 | Novartis Ag | Hydroxamate derivatives useful as deacetylase inhibitors |
WO2002055017A2 (en) * | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
Non-Patent Citations (8)
Title |
---|
GOTTLICHER M. ET AL.: "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells", EMBO J., vol. 20, no. 24, 2001, pages 6969 - 6978, XP002975647 * |
HAN J.-W. ET AL.: "Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin", CANCER RES., vol. 60, no. 21, 2000, pages 6068 - 6074, XP002960288 * |
JOHNSTONE R.W. ET AL.: "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", NAT. REV. DRUG DISCOV., vol. 1, no. 4, April 2002 (2002-04-01), pages 287 - 299, XP002975646 * |
NAKAJIMA H. ET AL.: "FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor", EXP. CELL. RES., vol. 241, no. 1, 1998, pages 126 - 133, XP002928826 * |
NAOKI ISHIGURO: "Mansei kansetsu rheumatism to saibogai matrix hakai", IGAKU NO AYUMI, vol. 177, no. 1, 1996, pages 81 - 85, XP002975645 * |
RICHON V.M. ET AL.: "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylase", PROC. NATL. ACAD. SCI. USA, vol. 95, no. 6, 1998, pages 3003 - 3007, XP001120542 * |
SAITO A. ET AL.: "A synthetic inhibitor of histone deacetylase, MS-27-275m, with marked in vivo antitumor activity against human tumors", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 8, 1999, pages 4592 - 4597, XP002158228 * |
WARRELL R.P. JR. ET AL.: "Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase", J. NATL. CANCER INST., vol. 90, no. 21, 1998, pages 1621 - 1625, XP002928827 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000282A3 (en) * | 2003-06-25 | 2005-04-28 | G2M Cancer Drugs Ag | Inhibitors of histone deacetylases for the suppression therapy of diseases |
US7892833B2 (en) | 2003-06-25 | 2011-02-22 | Topotarget Germany Ag | Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions |
KR100844061B1 (ko) * | 2005-02-05 | 2008-07-04 | 재단법인서울대학교산학협력재단 | 히스톤 탈아세틸라제에 대한 저해제 및 이를 이용한 골다공증의 치료 방법 |
EP1719508A1 (en) * | 2005-05-06 | 2006-11-08 | Yih-Lin Chung | Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7741494B2 (en) | 2005-07-14 | 2010-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
US9259452B2 (en) | 2006-06-08 | 2016-02-16 | Gelgene Corporation | Deacetylase inhibitor therapy |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
JP2010510302A (ja) * | 2006-11-23 | 2010-04-02 | ユニバーシティ、オブ、サウサンプトン | デプシペプチドおよびその治療的使用 |
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
JP2011529023A (ja) * | 2008-05-22 | 2011-12-01 | カルス セラピューティクス リミテッド | デプシペプチドおよびその治療的使用 |
WO2010013498A1 (ja) | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | 変形性関節症治療剤又は予防剤 |
WO2011093081A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療剤を含有する注射剤 |
WO2011093083A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
US9200077B2 (en) | 2010-01-29 | 2015-12-01 | Axis, Inc. | Injectable solution containing therapeutic agent for osteoarthritis |
WO2011093082A1 (ja) | 2010-01-29 | 2011-08-04 | Axis株式会社 | 変形性関節症治療剤または予防剤を製造するための使用 |
US9518094B2 (en) | 2010-07-12 | 2016-12-13 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9624271B2 (en) | 2010-07-12 | 2017-04-18 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9468664B2 (en) | 2013-12-27 | 2016-10-18 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9782451B2 (en) | 2013-12-27 | 2017-10-10 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9795650B2 (en) | 2013-12-27 | 2017-10-24 | Celgene Corporation | Romidepsin formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2009137979A (ja) | 2009-06-25 |
EP1547617A4 (en) | 2009-04-29 |
CA2495354A1 (en) | 2004-03-04 |
EP1547617B1 (en) | 2010-04-28 |
ATE465757T1 (de) | 2010-05-15 |
JPWO2004017996A1 (ja) | 2005-12-08 |
DE60332367D1 (de) | 2010-06-10 |
AU2003254951A1 (en) | 2004-03-11 |
EP1547617A1 (en) | 2005-06-29 |
US20050272647A1 (en) | 2005-12-08 |
ES2342378T3 (es) | 2010-07-06 |
JP4804004B2 (ja) | 2011-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004017996A1 (ja) | 関節軟骨細胞外マトリクス分解阻害剤 | |
JP4732693B2 (ja) | 最終分化を誘導する方法 | |
EP0827743B1 (en) | Use of histone decarboxylase inhibitors for treating fibrosis | |
AU2003219803B2 (en) | Method of treating TRX mediated diseases | |
CN1843508A (zh) | 治疗胃肠不适的医药组合物 | |
WO2011113013A2 (en) | Methods and compositions for treating viral or virally-induced conditions | |
TW202035415A (zh) | 用於治療骨關節炎的化合物 | |
KR20140091310A (ko) | 이소플라본을 포함하는 관절염 예방 및 치료용 약학적 조성물 | |
WO2006101163A1 (ja) | 運動器疾患の治療・予防用医薬組成物 | |
CN100569281C (zh) | 治疗和预防坏死的组合物的制备用途 | |
US11744821B2 (en) | Compositions and methods for treating defects in avascular cartilaginous tissue by directly administering one or more metabolites of simvastatin | |
KR20210155416A (ko) | 자세오시딘(Jaceocidin)을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
JP4359173B2 (ja) | 放射線療法および化学療法における治療効果を増大するための方法 | |
WO2005102332A1 (ja) | 変形性関節症治療剤 | |
CN113577051A (zh) | 一种维拉帕米在制备保护软骨细胞缓解骨关节炎的产品中的应用 | |
JP2019123679A (ja) | Mmp13発現抑制剤及びそれを利用した変形性関節症治療薬 | |
AU2005227400B2 (en) | Method of Treating TRX Mediated Diseases | |
AU2008202913B2 (en) | Method of Treating TRX Mediated Diseases | |
Luan et al. | Recent Advances in Pharmacotherapy for Peyronie's Disease | |
WO2000078305A1 (fr) | Remedes contre la polyarthrite rhumatoide | |
Gao et al. | Evodiamine Protects Against Inflammatory Response Via CaMKII and NF-κB Pathways in Osteoarthritis | |
JP2001064168A (ja) | 変形性関節症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004530568 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2495354 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003792716 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525015 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003792716 Country of ref document: EP |